Hedy Kindler to Piperazines
This is a "connection" page, showing publications Hedy Kindler has written about Piperazines.
Connection Strength
1.753
-
Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib. Ann Oncol. 2019 12 01; 30(12):1959-1968.
Score: 0.526
-
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med. 2019 07 25; 381(4):317-327.
Score: 0.508
-
Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma. Lung Cancer. 2004 Aug; 45 Suppl 1:S125-7.
Score: 0.182
-
Patient-centered outcomes in the POLO study of active maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. Cancer. 2023 05 01; 129(9):1411-1418.
Score: 0.164
-
Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer. J Clin Oncol. 2022 12 01; 40(34):3929-3939.
Score: 0.158
-
Maintenance Olaparib for Metastatic Pancreatic Cancer. Reply. N Engl J Med. 2019 10 10; 381(15):1492-1493.
Score: 0.130
-
A review of resistance patterns and phenotypic changes in gastrointestinal stromal tumors following imatinib mesylate therapy. J Gastrointest Surg. 2007 Jun; 11(6):758-66.
Score: 0.055
-
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther. 2011 Jul 01; 12(1):9-46.
Score: 0.018
-
Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res. 2006 Jan 01; 66(1):352-61.
Score: 0.013